Tuesday, October 28, 2025 10/28/2025

TLR Agonist Nano-Immune Therapy for Peritoneal Metastases

Award Number: R01CA293942
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/09/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

TLR Agonist Nano-Immune Therapy for Peritoneal Metastases - Summary Peritoneal metastases are present at diagnosis in 57% of women with ovarian cancer and 8% of patients with colorectal cancer. Peritoneal metastases have been considered a terminal condition for the majority of patients, but emerging evidence of immune advantages associated with intraperitoneal administration presents opportunities to advance novel therapeutics for these cancers. Despite a strong rationale for immune therapy in ovarian cancer, immune checkpoint inhibitors have not demonstrated efficacy in clinical trials for ovarian cancer, and novel approaches are needed for this disease. Our preclinical studies demonstrated that intraperitoneal delivery of mesoporous silica nanoparticles (MSN) functionalized with Toll-like receptor (TLR) agonists leads to rapid internalization by free and spheroid-associated CD11b+ myeloid cells with subsequent trafficking to tumor implants, rather than sequestration in the liver as seen following intravenous delivery. Furthermore, intraperitoneal delivery of TLR agonist-modified MSN eliminated disseminated peritoneal ovarian cancer and protected against tumor rechallenge. In contrast, subcutaneous delivery did not demonstrate therapeutic efficacy, highlighting the impact of route of delivery and local interactions with tumor infiltrating leukocytes. This project seeks to define mechanisms whereby intraperitoneally administered modified-MSN achieves tumor eradication with a focus on delivery route, trafficking, toxicodynamic properties, efficacy in diverse models of peritoneal metastases, and activation of murine and human immune cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $464,569 )
2025	2025	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Cancer Treatment Research	000	2	8/12/2025	NON-COMPETING CONTINUATION	$464,569
														Subtotal = $464,569

Issue Date FY: 2024 ( Subtotal = $483,556 )
2024	2024	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Cancer Treatment Research	000	1	9/9/2024	NEW	$483,556
														Subtotal = $483,556

Grand Total All Awards = $948,125

Top

All Categories

About

Search

Reports

Data Submission

Award Information

TLR Agonist Nano-Immune Therapy for Peritoneal Metastases

Award Number: R01CA293942

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/09/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer